Clinical Trials on Diabetes Mellitus

Total 20275 results

Novo Nordisk A/S

Completed

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novartis

Completed

Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

Diabetes Mellitus, Type 2

Switzerland
Novartis

Completed

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, Norway
Novo Nordisk A/S

Completed

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, United Kingdom, Sweden, Finland
Novo Nordisk A/S

Completed

Initiation of Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

France
Novo Nordisk A/S

Completed

Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

Diabetes Mellitus, Type 2 | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Spain
Novo Nordisk A/S

Completed

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen (Full STEP™)

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Argentina, Macedonia, The Former Yugoslav Republic of, Slovenia, Canada, Brazil
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes (SOLVE™)

Diabetes Mellitus, Type 2 | Diabetes

Israel, Spain, China, Turkey, Germany, Poland, Italy, Canada, Portugal
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Denmark, Spain, Norway, Italy, France, Netherlands
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Germany, United Kingdom, Austria, Belgium, France, Ireland
Novo Nordisk A/S

Completed

Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Belgium, United Kingdom, Slovenia
Novo Nordisk A/S

Completed

Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes (ROOTS)

Diabetes Mellitus, Type 2 | Diabetes

Belgium
Novo Nordisk A/S

Completed

A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-1)

Diabetes Mellitus, Type 2 | Diabetes

Israel, Poland, Switzerland, Argentina, India, Malaysia, South Africa, Taiwan, Finland, France, Turkey, Croatia, Italy, Bulgaria, Romania, Australia, Thailand, Greece, Brazil, Spain, Korea, Republic of, Czech Republic, Philippines
Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada
Novo Nordisk A/S

Completed

Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, United Kingdom, Norway
Novo Nordisk A/S

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Completed

Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin (Mix2Mix)

Diabetes Mellitus, Type 2 | Diabetes

Belgium, Luxembourg
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment (Start)

Diabetes Mellitus, Type 2 | Diabetes

Finland
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes (PRESENT)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, United Kingdom, Spain, Denmark, France, Netherlands, Austria, Hungary, Russian Federation, Germany, Turkey, Italy, Bulgaria, Romania, Belgium, Switzerland, Slovenia, Czech Republic
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-F1)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Romania, Ukraine, Germany, Italy, Estonia, Malaysia, Philippines, Mexico, Lithuania, Colombia, Slovakia, Chile
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, India, Belgium, Mexico, Tunisia, Japan, Israel, Korea, Republic of
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
Novo Nordisk A/S

Completed

An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries (BO2NE)

Diabetes Mellitus, Type 2 | Diabetes

Israel, Jordan, Pakistan, Lebanon
Novartis Pharmaceuticals

Completed

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt

Clinical Trials on Diabetes Mellitus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations